LIVE
WDC$260.94-32.84 (-11.18%)|GOOGL$265.56-8.34 (-3.04%)|INTC$51.34-3.78 (-6.86%)|ORCL$101.11-8.90 (-8.09%)|AMD$423.55-57.50 (-11.95%)|NVO$37.81-1.08 (-2.78%)|JNJ$270.90+4.90 (+1.84%)|NOC$534.11-4.44 (-0.82%)|AVGO$304.02-42.98 (-12.39%)|MRVL$121.89-16.41 (-11.87%)|TSLA$346.25-26.52 (-7.11%)|VST$115.16-6.84 (-5.61%)|VRT$166.15-16.55 (-9.06%)|TSM$319.17-30.93 (-8.83%)|TER$204.52-19.58 (-8.74%)|SMCI$21.66-2.04 (-8.61%)|RCL$296.49-5.81 (-1.92%)|QBTS$6.49-0.82 (-11.22%)|OKLO$20.00+ (+%)|NVDA$125.90-19.77 (-13.57%)|WDC$260.94-32.84 (-11.18%)|GOOGL$265.56-8.34 (-3.04%)|INTC$51.34-3.78 (-6.86%)|ORCL$101.11-8.90 (-8.09%)|AMD$423.55-57.50 (-11.95%)|NVO$37.81-1.08 (-2.78%)|JNJ$270.90+4.90 (+1.84%)|NOC$534.11-4.44 (-0.82%)|AVGO$304.02-42.98 (-12.39%)|MRVL$121.89-16.41 (-11.87%)|TSLA$346.25-26.52 (-7.11%)|VST$115.16-6.84 (-5.61%)|VRT$166.15-16.55 (-9.06%)|TSM$319.17-30.93 (-8.83%)|TER$204.52-19.58 (-8.74%)|SMCI$21.66-2.04 (-8.61%)|RCL$296.49-5.81 (-1.92%)|QBTS$6.49-0.82 (-11.22%)|OKLO$20.00+ (+%)|NVDA$125.90-19.77 (-13.57%)|

Datenschutz & Cookies

Wir nutzen Cookies, um diese Website zu betreiben und zu verbessern. Einige sind technisch notwendig, andere helfen uns, die Nutzung zu verstehen. Du kannst frei wählen, welche du erlaubst. Datenschutz

Johnson & Johnson

Johnson & Johnson

JNJ·NASDAQ
Analysis date:November 21, 2026
Current price
$270.90+4.90(+1.84%)
52W High:$290.25
|
52W Low:$199.91

NextSignal Score™

AI-powered rating

56of 100
Neutral
Fundamentals
16
Max: 25
Neutral
Valuation
23
Max: 25
Low
Risk
9
Max: 20
Medium
Trend
3
Max: 15
Neutral
Momentum
5
Max: 15
Weak
Market assessment JNJ
Key signals
Hold
No clear trend – wait-and-see approach warranted.
Price
$270.90
Target Zone
$276*
Support
$264
Analysts
Buy
Conclusion
The technical situation is neutral, supported by a solid positioning above the EMA200 but tempered by weaker momentum. The NextSignal Score of 56/100 underscores the market's wait-and-see approach.
*Target zone is an analyst estimate and provides no guarantee that this level will be reached.

Stock Analysis Summary

16/25
Fundamentals

Moderates Umsatzwachstum, Negatives EPS-Wachstum, Hohe Bruttomarge, Starke Eigenkapitalrendite.

23/25
Valuation

KGV 24.4 – günstig, KUV attraktiv, KBV attraktiv, Analysten bullish.

9/20
Risk

Negativer Trend, Beta 0.19 – defensiv.

3/15
Trend

Abwärtstrend aktiv.

5/15
Momentum

RSI 44.6 – neutrales Momentum.

Analyst Consensus30 Analysts · 2026-11-01
Buy
30
Analysts
Buy
70%
Hold
30%
Sell
0%

Johnson & Johnson stock is currently trading at $270.47, moving within a neutral market environment.

🚀 What is happening currently?

Johnson & Johnson continues to advance its strategic focus in the fields of medical technology and biotechnology. The company recently announced the first commercial installation of the OTTAVA™ robotic system in a US hospital, marking a significant milestone for the division. Furthermore, the company is strengthening its pipeline through the planned acquisition of Ollin Biosciences for $2.2 billion to expand its presence in ophthalmology. These moves underscore a focus on innovation, even as the company remains confronted with the challenges of ongoing legal disputes.

🔍 Technical Analysis

The current price of $270.47 is above the EMA50 ($269.04) and the EMA200 ($248.57), suggesting an improved broader trend, while it remains just below the EMA20 ($273.64). With an RSI of 49.9, the stock is moving in a neutral zone. The MACD at 2.480 is below the signal value of 3.780, indicating weakening momentum. The stock is trading below resistance at $275.53, while the next support levels are at $263.83 and $260.68. Since the price is significantly below the 52W high of $290.25 but well above the 52W low of $199.91, the price structure appears consolidated, albeit currently moving sideways.

📊 Fundamental Situation

The fundamental data reflects a company growing through targeted acquisitions and product innovations. An EPS of $2.9371 is expected for the coming quarter, with quarterly results scheduled for 01/26/2027. As the company has historically faced special charges due to legal disputes, profitability is significantly influenced by the operational implementation of new strategies. The fundamental data is somewhat complex, as it includes both strong operational cash flows and the costs associated with strategic investments.

🎯 Analyst Expectations

Analysts currently rate the stock mostly as cautious to neutral. The average price target is above the current level, implying limited upside potential.

💡 Market Assessment

With a NextSignal Score of 56/100, the stock is classified as neutral. This value reflects the current uncertainty arising from the combination of sideways technical movement and fundamental challenges. There is currently no signal justifying a clear trend in either direction. Investors should closely monitor further developments regarding legal disputes as well as the integration of new technologies. A neutral stance is appropriate given the current data.

🔍 What to watch for

  1. Legal disputes: Potential new developments or provisions in connection with the talc lawsuits could weigh on the share price in the short term.
  2. OTTAVA market launch: The success of the commercial rollout of the robotic system is crucial for the growth of the MedTech division.
  3. Pipeline integration: The successful integration of Ollin Biosciences and progress in clinical trials are essential for long-term valuation.

Technical analysis

Last 60 trading days · Live data from Yahoo Finance

Price Chart + EMA 20 / 50 / 200
28.0814.0928.0912.1026.1009.11$233$248$263$292
2026-11-20
Kurs270.47
EMA 20273.64
EMA 50269.04
EMA 200248.57
Kurs
EMA 20
EMA 50
EMA 200
RSI (14)
28.0814.0928.0912.1026.1009.1102550100OBOS
2026-11-20
RSI49.92
MACD
28.0814.0928.0912.1026.1009.11-6-306
2026-11-20
Histogramm-1.30
MACD2.48
Signal3.78
What does the chart show?
  • • Price action over the last few weeks at a glance.
  • • EMA lines help identify the prevailing trend direction.

Fundamentals & News

Live data

Company

Johnson & Johnson

Johnson & Johnson

NEW YORK STOCK EXCHANGE, INC.·Pharmaceuticals
Market Cap: USD 651.1B

Johnson & Johnson is a US-based multinational corporation primarily operating in the pharmaceutical industry. The company develops, manufactures, and distributes a diverse range of medical products and pharmaceutical solutions for global healthcare. Its core business focuses on the research and development of innovative medicines and advanced medical technologies.

Fundamentals

Key metrics

Forward P/E
24.29
52W High
290.25$
52W Low
199.91$
Beta
0.18
EPS (TTM)
6.59$
Dividend Yield
3.12%
ROE
19.55%
Gross Margin
67.69%